Navigation Links
Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents
Date:6/17/2009

ident and CEO of EthiX Associates, a pharmaceutical and biotech consultancy he founded in 1996. He has also served as the President and CEO of GenBioPro, Inc., a specialty biopharmaceutical company focused on the development and marketing of "biosimilar" products, and INSYS Therapeutics, Inc., a privately held biopharmaceutical company with a focus on chemotherapy induced nausea and vomiting, pain management and CNS disorders.

He held the positions of the Chairman, President, and CEO of the Arizona BioIndustry Association from 2004 to 2007.

Mr. McGarity was President and Chief Operating Officer and then Vice Chairman of Pharmaceutical Marketing Services, Inc. from 1991 to 1996.

He was employed by GlaxoSmithKline (then Glaxo) from 1987 to 1991. Over that time he served as Vice President in the Corporate Division; Vice President of National Accounts; Vice President and General Manager of the Glaxo Dermatology group; and Director of Managed Health Care.

From 1981 to 1986, Mr. McGarity worked as Vice President of Sales and Marketing at Westwood Pharmaceuticals, the specialty pharmaceuticals division of Bristol Myers Squibb.

From 1965 to 1981 he was employed by Novartis Pharmaceuticals (then Sandoz) having worked throughout the ranks of their commercial organization as a sales representative, hospital representative, product manager, district manager, and Director of Sales and Marketing in Canada and the United States.

Mr. McGarity is a Board Director at Cypress Biosciences Inc. (CYPB), and also serves on the Boards of several early stage pharma/biotech companies including Apthera, GenBioPro, SynBuild, MedApps, Inc., and Restorative Biosciences. He also sits of the Boards of a number of life science organizations and university programs including the Arizona BioIndustry Association and the Global Advisory Council at Thunderbird School of Global Management
'/>"/>

SOURCE Campbell Alliance
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY
2. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
3. Campbell Alliance Hires Joe Dillon, Expands Business Development Practice
4. Campbell Alliance Sales Practice to Present at CBIs Leadership Summit on Evolving the Pharma Sales Model
5. Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
6. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
7. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
8. Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting
9. Campbell Alliance Trade and Distribution Practice to Speak at CBIs Commercial Contracts and Chargeback Management Conference
10. Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference
11. Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... $2.25 to $2.35., ST. LOUIS, Oct. 23 , HIGHLIGHTS:, ... periods in 2006):, -- Strongest Quarterly Sales Growth in 2007: ... prior quarters, performance, with reported quarterly growth ... high sales achieved in Q2 2007. Organic ...
... Roche Releases Positive Phase I Results for R1507, ... positive results from a Phase I study of R1507 ... R1507 is a human,monoclonal antibody targeting the insulin-like growth ... Genmab. Nine of 34 adult patients with solid ...
... Va., Oct. 23 PRA International,(Nasdaq: PRAI ) ... of therapeutic expertise and a specialist in oncology and,hematology, ... in oncology on Thursday, Nov. 8, 2007 at 11:30 ... Berger will,recommend ways to mitigate risk in terms of ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 2Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 3Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 4Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 5Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 6Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 7Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 8Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 9Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 10Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 11Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 12Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 13Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 14Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 15Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 16Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 17Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 18Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 19Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 20Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 2Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 3PRA International to Present Audioconference on Oncology Research - Nov. 8 2
(Date:12/17/2014)... Va. , Dec. 15, 2014 The Defense ... easier to detect and prevent counterfeit microcircuits from entering ... started performing an in-house microcircuit anti-counterfeit initiative dubbed DNA ... microcircuits while increasing their reliability throughout the supply chain. ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... suppression therapy to prevent T cell-mediated rejection. These ... undesirable side effects. Therefore, specific suppression of the ... needed. , It was known that anergic T ... to antigen stimulation) generated in an artificial environment ...
... culprits in delivering pollutants ?through their guano ?to seemingly ... The most common form of wildlife in the Arctic, ... contaminants to some coastal ecosystems, the researchers found. "The ... mercury and DDT to as much as 60 times ...
... biggest questions in modern oceanography is how animals in ... at the Monterey Bay Aquarium Research Institute (MBARI) recently ... least for animals that live on the deep seafloor ... of hours of deep-sea video, Bruce Robison and his ...
Cached Biology News:Industrial contaminants spread by seabirds in High Arctic, new Canadian study shows 2'Sinkers' provide missing piece in deep-sea puzzle 2'Sinkers' provide missing piece in deep-sea puzzle 3'Sinkers' provide missing piece in deep-sea puzzle 4
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
RABBIT ANTI NEOPTERIN...
... Dog serum is collected from fasted mixed breed, ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
Biology Products: